Oncology

Latest News

Insurance gaps | Image Credit: iQoncept-stock.adobe.com

Insurance Gaps Threaten Cancer Treatment Success

By Maggie L. Shaw

July 7th 2025

Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

July 8th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 8th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

March 18th 2015

Radioactive Nanoparticles to Specifically Target Neuroblastomas

Developed at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, the technology uses tiny radioactive liposomes, inserted directly into a tumor with a thin catheter. The first-in-human trial was just initiated.

March 18th 2015

Discovery Points to Role of Macrophages in Melanoma Drug Resistance

Researchers have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments, they say. The results were published in the journal Clinical Cancer Research.

Session on Cardio-Oncology Reflects Growing Number of Survivors

March 17th 2015

Session on Cardio-Oncology Reflects Growing Number of Survivors

The Cardio-Oncology Intensive during the Annual Scientific Session of the American College of Cardiology reflects the increased need for improved diagnostic tools and cardioprotective strategies as cancer patients live longer. Besides a second malignancy, heart disease accounts for most morbidity and death in cancer survivors.

March 17th 2015

QALY: A Barrier for Patient Access to New Anticancer Agents?

The report by IMS Institute for Healthcare Informatics says countries that use a QALY formula to assess cost-effectiveness have less access to new cancer drugs compared with countries that use an alternative system.

March 17th 2015

Encouraging Results from Imbruvica in CLL and Small Lymphocytic Lymphoma

Improved survival without disease progression prompted independent reviewers to unblind the study comparing Imbruvica against a placebo, in combination with bendamustine and rituximab.

March 16th 2015

Circulating Plasma DNA Could be a Viable Alternative to Tumor Biopsy

The diagnostic test, which has been validated in breast, lung, colorectal, skin, and prostate cancers, requires sample submission to Guardant's CLIA-certified laboratory. The test, currently priced at $4900, maybe covered by payers where genomic profiling is needed and conventional biopsy is not an option.

March 16th 2015

Oncologists Raise a Voice Against Cancer Drug Costs

Hagop Kantarjian, MD, from MD Anderson is at it again. A special publication online, written in collaboration with S. Vincent Kumar, MD, from the Mayo Clinic, highlights the dismal state of the economics behind high oncology drug costs and recommends solutions.

Augmenting the Immune System to Achieve Great Outcomes in Cancer Care

March 15th 2015

Augmenting the Immune System to Achieve Great Outcomes in Cancer Care

Laura Joszt, MA

During the session "Principles of Immunotherapy" at the National Comprehensive Cancer Network 20th Annual Conference, Anthony J. Olszanski, RPh, MD, from the Fox Chase Cancer Center, described the complex interplay between the immune system and cancer, and some of the current immunotherapies being used today.

Dr Clifford Goodman Outlines the Pros and Cons of NCCN Guidelines

March 14th 2015

Dr Clifford Goodman Outlines the Pros and Cons of NCCN Guidelines

Over the years, the National Comprehensive Cancer Network Guidelines have become the market leader for clinical guidelines to consult, but with that success comes responsibility and scrutiny, according to Clifford Goodman, PhD.

Mary Lou Smith on Bringing Better Cancer Care to the Community

March 14th 2015

Mary Lou Smith on Bringing Better Cancer Care to the Community

The National Comprehensive Cancer Network Guidelines bring the practices of cancer care thought leaders out to the community, said Mary Lou Smith, JD, MBA, co-founder of the Research Advocacy Network.

NCCN Unveils New Smoking Cessation Guidelines

March 14th 2015

NCCN Unveils New Smoking Cessation Guidelines

Laura Joszt, MA

The most recent Surgeon General Report on Smoking and Health initiated the decision to create smoking cessation guidelines for cancer patients, Peter G. Shields, MD, said during his session announcing the new NCCN Guidelines.

Linda House Highlights the Effect of Strong Patient-Physician Relationships

March 14th 2015

Linda House Highlights the Effect of Strong Patient-Physician Relationships

Patient-provider dialogue before making treatment decisions affects how satisfied patients are with their overall care, Linda House, RN, BSN, MSM, president of the Cancer Support Community, said at the National Comprehensive Cancer Network 20th Annual Conference.

NCCN Guidelines Become Resource Stratified for Global Use

March 13th 2015

NCCN Guidelines Become Resource Stratified for Global Use

Laura Joszt, MA

Resource constraints may confine the ability of physicians to deliver optimal cancer care to all patients across the world, which the National Comprehensive Cancer Network is acknowledging by resource stratifying its Guidelines.

Dr Peter Bach Explains Diminishing Returns in Cancer Drugs

March 13th 2015

Dr Peter Bach Explains Diminishing Returns in Cancer Drugs

While the cost of introductory cancer drugs is increasing rapidly, there has not been a commensurate increase in benefit, according to Peter Bach, MD, with Memorial Sloan Kettering Cancer Center.

March 13th 2015

NCCN Recommends Only One Test for Breast Cancer, Says Expert

According to Dr Amy Cyr from the Siteman Cancer Center at Washington University in St. Louis, Missouri, while Oncotype DX is both prognostic and predictive, none of the other tests currently available have shown both capabilities.

March 13th 2015

Low Breast Density Could Indicate Poor Prognosis, Study Suggests

The findings of this study, conducted in Finland, may prove significant for the assessment of breast cancer prognosis and treatment planning.

March 13th 2015

CDC Report Underscores Impact of Early Diagnosis and Innovation on Cancer Survival

Two out of three people with metastatic disease survive 5 years or more, the report shows. The authors hope the data can help researchers develop better cancer control programs.

20 Years of Creating and Embracing Guidelines in Cancer Care

March 13th 2015

20 Years of Creating and Embracing Guidelines in Cancer Care

Laura Joszt, MA

When the first National Comprehensive Cancer Network Guidelines were developed 20 years ago, even the participating members who were there at the beginning were skeptical they would be able to come to an agreement and build something lasting.

March 13th 2015

Geography Determines Appropriate Use of Imaging in Low-Risk Cancer Patients

The study, published in JAMA Oncology, found that low risk breast and prostate cancer patients received unnecessary imaging overall, with a higher rate observed in the North East region of the country.

March 12th 2015

ACS Study Recommends Increased Screening to Reduce Incidence of Colorectal Cancer

The study, published in the journal Cancer found that increasing screening rates to 80% by 2018 would reduce projected colorectal cancer incidence rates by 17% and mortality rates by 19% during short-term follow-up, and by 22% and 33%, respectively, during extended follow-up. Those reductions would amount to a total of 277,000 averted new cancers and 203,000 averted colorectal cancer deaths from 2013 through 2030.

Dr Robert Carlson Highlights Top NCCN Meeting Takeaway

March 12th 2015

Dr Robert Carlson Highlights Top NCCN Meeting Takeaway

The National Comprehensive Cancer Network (NCCN) Guidelines may be successful historically, but the network isn't resting on its laurels, Robert Carlson, MD, chief executive officer, said at the NCCN 20th Annual Meeting.

Transforming the NCCN Guidelines

March 12th 2015

Transforming the NCCN Guidelines

Laura Joszt, MA

During his keynote speech at the National Comprehensive Cancer Network (NCCN)'s 20th Annual Conference, Chief Executive Officer Robert Carlson, MD, spent the majority of his time discussing the NCCN Guidelines because they are the core of its services.

March 12th 2015

A New Strategy for Payers to Cover High Cost Specialty Medications?

A new analysis published by the RAND Corporation suggests strategies that the pharmaceutical industry could offer payers as they try to cover the front-loaded cost of newer breakthrough drugs.

March 12th 2015

Dietary Restrictions Could Prevent Colon Cancer

The study, published in JAMA Internal Medicine, found that while the complete absence of meat in the diet had the most impact on reducing the risk of colorectal cancer, those who added seafood to the vegetarian diet-pescovegetarians-faired better than the nonvegetarians.

March 12th 2015

Study Shows Experienced Care Facilities Improve Survival in NSCLC

The study, published in the Journal of Thoracic Oncology, found that patients treated with definitive concurrent chemotherapy and radiation therapy for stage 3 non-small cell lung cancer have longer overall survival when treated by highly experienced facilities, either academic or community cancer centers.

March 11th 2015

Myriad's Gene Panel Could Diagnose Metastatic Melanoma

The 23-gene diagnostic panel called myPath Melanoma could be used in addition to microscopy to distinguish the benign form of the disease from malignant disease.

March 11th 2015

Scientist Whose Discoveries Helped Develop Ipilimumab Among ASCO Honorees

The awards will be presented at ASCO's annual meeting to be held in Chicago in May this year.

March 11th 2015

NICE Recommends Gazyvaro for Treatment-Naive CLL Patients

The recommendation has not come easy for Roche. Back in October 2014, NICE had rejected Gazyravo based on inconsistencies in the filing, which were then addressed by the drug manufacturer. Subsequently, NICE struck a deal with Roche to provide the drug to NHS at a reduced price.

March 10th 2015

Escalating Drug Prices Not a Concern for All

While the PBM Express Scripts declared plans to bring cancer drug plans down, the drug manufacturers and investors aren't too worried about the high cost of some of the specialty drugs, according to this article in Bloomberg.

March 10th 2015

Breast Cancer Survivors Have Increased Risk of Thyroid Cancer

Laura Joszt, MA

Within 5 years of a breast cancer diagnosis, patients are at an increased risk of developing thyroid cancer, according to a new study, which was presented at the Endocrine Society's 97th annual meeting.

...

136 137 138 139 140 141 142 143 144

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions